Shattuck Labs: "Hold" On Oncology Exit And Competitive TL1A/DR3 Pathway Pivot

2026-01-16 13:31:18 ET

The last time I spoke about Shattuck Labs ( STTK ) it was in a prior Seeking Alpha article entitled " Shattuck Labs: Positive Blood Cancer Data Leads To Mid-2024 Catalyst ". With respect to this article, I mentioned that the company had released some positive results from its phase 1A/B study using its drug SL-172154 in combination with azacitidine for the treatment of patients with front-line [1st-line] higher-risk myelodysplastic syndrome [HR-MDS] and TP53-mutant acute myeloid leukemia. At that time, I had placed a "Buy" rating on this stock because of this program. Unfortunately, things didn't go well later on because while the data was decent, it was shown that the combination was not that much better at treating these patients than azacitidine alone....

Read the full article on Seeking Alpha

For further details see: